Dataset.
Supporting information Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312885
Digital.CSIC. Repositorio Institucional del CSIC
- Calvo-Lozano, Olalla
- Sierra, Miquel
- Soler, María
- Estévez, M. Carmen
- Chiscano- Camón, Luis
- Ruiz-Sanmartín, Adolfo
- Ruiz-Rodriguez, Juan Carlos
- Ferrer, Ricard
- González-López, Juan José
- Esperalba, Juliana
- Fernández-Nava, Candela
- Bueno, Leticia
- López-Aladid, Rubén
- Torres, Antoni
- Fernández-Barat, Laia
- Attoumani, Sarah
- Charrel, Remi
- Coutard, Bruno
- Lechuga, Laura M.
15 pages. -- Content: 1. Supplementary text: 1.1.Chemical and biological reagents; 1.2.SPR biosensor device; 1.3.Plasmonic sensor chip preparation; 1.4.Clinical samples collection; 1.5.Stratification of convalescent COVID patients. Samples collection from Clinic Hospital (Barcelona); 1.6. Standard analytical techniques (ELISA, CLIA and LFA); 1.7.Data analysis; 1.8.Diagnostic sensitivity and specificity. -- 2. Figures. -- Tables S1-S3. -- References., Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., Peer reviewed
DOI: http://hdl.handle.net/10261/312885
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312885
HANDLE: http://hdl.handle.net/10261/312885
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312885
Ver en: http://hdl.handle.net/10261/312885
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312885
No hay resultados en la búsqueda
No hay resultados en la búsqueda
×
1 Versiones
1 Versiones
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312885
Dataset. 2021
SUPPORTING INFORMATION LABEL-FREE PLASMONIC BIOSENSOR FOR RAPID, QUANTITATIVE, AND HIGHLY SENSITIVE COVID-19 SEROLOGY: IMPLEMENTATION AND CLINICAL VALIDATION
Digital.CSIC. Repositorio Institucional del CSIC
- Calvo-Lozano, Olalla
- Sierra, Miquel
- Soler, María
- Estévez, M. Carmen
- Chiscano- Camón, Luis
- Ruiz-Sanmartín, Adolfo
- Ruiz-Rodriguez, Juan Carlos
- Ferrer, Ricard
- González-López, Juan José
- Esperalba, Juliana
- Fernández-Nava, Candela
- Bueno, Leticia
- López-Aladid, Rubén
- Torres, Antoni
- Fernández-Barat, Laia
- Attoumani, Sarah
- Charrel, Remi
- Coutard, Bruno
- Lechuga, Laura M.
15 pages. -- Content: 1. Supplementary text: 1.1.Chemical and biological reagents; 1.2.SPR biosensor device; 1.3.Plasmonic sensor chip preparation; 1.4.Clinical samples collection; 1.5.Stratification of convalescent COVID patients. Samples collection from Clinic Hospital (Barcelona); 1.6. Standard analytical techniques (ELISA, CLIA and LFA); 1.7.Data analysis; 1.8.Diagnostic sensitivity and specificity. -- 2. Figures. -- Tables S1-S3. -- References., Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., Peer reviewed
No hay resultados en la búsqueda
1106